Initial Results of Secukinumab Drug Survival in Patients with Psoriasis : A Multicentre Daily Practice Cohort Study
Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily practice. The aim of this study was to evaluate drug survival of secukinumab in a daily practice psoriasis cohort. Data were collected from 13 hospitals. Drug survival was analysed using Kaplan-Meier survival curves, split for reason of discontinuation. In total, 196 patients were included (83% biologic experienced). Overall, 12 and 18 months drug survival of secukinumab was 76% and 67%, respectively, and was mostly determined by ineffectiveness. There was a trend towards shorter drug survival in women and in biologic experienced patients. Thirteen percent of patients experienced at least one episode of fungal infection. This is one of the first studies of drug survival of secukinumab in patients with psoriasis treated in daily practice.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
---|---|
Enthalten in: |
Acta dermato-venereologica - 98(2018), 7 vom: 11. Juli, Seite 648-654 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
van den Reek, Juul M P A [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal |
---|
Anmerkungen: |
Date Completed 29.10.2018 Date Revised 10.12.2019 published: Print Citation Status MEDLINE |
---|
doi: |
10.2340/00015555-2900 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM28064969X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM28064969X | ||
003 | DE-627 | ||
005 | 20231225025811.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2340/00015555-2900 |2 doi | |
028 | 5 | 2 | |a pubmed24n0935.xml |
035 | |a (DE-627)NLM28064969X | ||
035 | |a (NLM)29405245 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a van den Reek, Juul M P A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Initial Results of Secukinumab Drug Survival in Patients with Psoriasis |b A Multicentre Daily Practice Cohort Study |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.10.2018 | ||
500 | |a Date Revised 10.12.2019 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily practice. The aim of this study was to evaluate drug survival of secukinumab in a daily practice psoriasis cohort. Data were collected from 13 hospitals. Drug survival was analysed using Kaplan-Meier survival curves, split for reason of discontinuation. In total, 196 patients were included (83% biologic experienced). Overall, 12 and 18 months drug survival of secukinumab was 76% and 67%, respectively, and was mostly determined by ineffectiveness. There was a trend towards shorter drug survival in women and in biologic experienced patients. Thirteen percent of patients experienced at least one episode of fungal infection. This is one of the first studies of drug survival of secukinumab in patients with psoriasis treated in daily practice | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Dermatologic Agents |2 NLM | |
650 | 7 | |a secukinumab |2 NLM | |
650 | 7 | |a DLG4EML025 |2 NLM | |
700 | 1 | |a van Vugt, Lieke J |e verfasserin |4 aut | |
700 | 1 | |a van Doorn, Martijn B A |e verfasserin |4 aut | |
700 | 1 | |a van der Kraaij, Gayle E |e verfasserin |4 aut | |
700 | 1 | |a de Kort, Wim J A |e verfasserin |4 aut | |
700 | 1 | |a Lucker, Georges P H |e verfasserin |4 aut | |
700 | 1 | |a Horvath, Barbara |e verfasserin |4 aut | |
700 | 1 | |a Njoo, M David |e verfasserin |4 aut | |
700 | 1 | |a Bovenschen, H Jorn |e verfasserin |4 aut | |
700 | 1 | |a Ossenkoppele, Paul M |e verfasserin |4 aut | |
700 | 1 | |a De Bruin-Weller, Marjolein S |e verfasserin |4 aut | |
700 | 1 | |a de Groot, Marjan |e verfasserin |4 aut | |
700 | 1 | |a Mommers, Roland |e verfasserin |4 aut | |
700 | 1 | |a Prevoo, Ruud L M A |e verfasserin |4 aut | |
700 | 1 | |a van de Kerkhof, Peter C M |e verfasserin |4 aut | |
700 | 1 | |a Spuls, Phyllis I |e verfasserin |4 aut | |
700 | 1 | |a Kievit, Wietske |e verfasserin |4 aut | |
700 | 1 | |a de Jong, Elke M G J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Acta dermato-venereologica |d 1945 |g 98(2018), 7 vom: 11. Juli, Seite 648-654 |w (DE-627)NLM000480754 |x 1651-2057 |7 nnns |
773 | 1 | 8 | |g volume:98 |g year:2018 |g number:7 |g day:11 |g month:07 |g pages:648-654 |
856 | 4 | 0 | |u http://dx.doi.org/10.2340/00015555-2900 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 98 |j 2018 |e 7 |b 11 |c 07 |h 648-654 |